[
    [
        {
            "time": "2020-08-10",
            "original_text": "龙头凯莱英上半年营收净利润双增，服务海外大型制药公司所属药品收入占比超7成。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "营收",
                    "净利润",
                    "双增",
                    "海外制药公司"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "龙头凯莱英上半年营收净利润双增，服务海外大型制药公司所属药品收入占比超7成。",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "【财报智读】凯莱英：2020年上半年归母净利润3.16亿元，同比增长37.63%。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "归母净利润",
                    "同比增长",
                    "37.63%"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【财报智读】凯莱英：2020年上半年归母净利润3.16亿元，同比增长37.63%。",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "医药生物行业周报：中报窗口期继续看好业绩高增长板块，持续推荐有实力能兑现的疫苗公司。",
            "features": {
                "keywords": [
                    "医药生物",
                    "中报窗口期",
                    "业绩高增长",
                    "疫苗公司"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：中报窗口期继续看好业绩高增长板块，持续推荐有实力能兑现的疫苗公司。",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "医药行业周报：建议关注药店，关注业绩高增长、政策变化和估值性价比。",
            "features": {
                "keywords": [
                    "医药行业",
                    "药店",
                    "业绩高增长",
                    "政策变化",
                    "估值性价比"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业周报：建议关注药店，关注业绩高增长、政策变化和估值性价比。",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "社保基金长线坚守30只股（附股）。",
            "features": {
                "keywords": [
                    "社保基金",
                    "长线坚守",
                    "30只股"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "社保基金长线坚守30只股（附股）。",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "凯莱英一度拉涨8%！半年度净利润增加37%。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "拉涨8%",
                    "半年度净利润",
                    "增加37%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英一度拉涨8%！半年度净利润增加37%。",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "凯莱英（002821）2020年半年报点评：业绩恢复高增长，毛利率显著提升。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "半年报点评",
                    "业绩恢复高增长",
                    "毛利率显著提升"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英（002821）2020年半年报点评：业绩恢复高增长，毛利率显著提升。",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "【医药】海内外双拓高增长，毛利率提升强降本——凯莱英（002821）2020年半年报点评——增持（联系人：甘英健、陈晨、张山峰）。",
            "features": {
                "keywords": [
                    "凯莱英",
                    "海内外双拓",
                    "高增长",
                    "毛利率提升",
                    "强降本",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】海内外双拓高增长，毛利率提升强降本——凯莱英（002821）2020年半年报点评——增持（联系人：甘英健、陈晨、张山峰）。",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]